MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Use with caution

Zonisamide 50mg capsules (Milpharm Ltd)

Explore other Zonisamide formulations Explore other Zonisamide 50mg capsules suppliers

Stability Notes

Store in an airtight container. Protect from light.

Provenance

This compatibility recommendation is derived from Zonegran 50mg capsules (Advanz Pharma).

Use with caution

Zonisamide 50mg capsules (Necessity Supplies Ltd)

Explore other Zonisamide formulations Explore other Zonisamide 50mg capsules suppliers

Stability Notes

Store in an airtight container. Protect from light.

Provenance

This compatibility recommendation is derived from Zonegran 50mg capsules (Advanz Pharma).

Use with caution

Zonisamide 50mg capsules (Sovereign Medical Ltd)

Explore other Zonisamide formulations Explore other Zonisamide 50mg capsules suppliers

Stability Notes

Store in an airtight container. Protect from light.

Provenance

This compatibility recommendation is derived from Zonegran 50mg capsules (Advanz Pharma).

Use with caution

Zonisamide 50mg capsules (Teva UK Ltd)

Explore other Zonisamide formulations Explore other Zonisamide 50mg capsules suppliers

Stability Notes

Store in an airtight container. Protect from light.

Provenance

This compatibility recommendation is derived from Zonegran 50mg capsules (Advanz Pharma).

Use with caution

Zonisamide 50mg capsules (Viatris UK Healthcare Ltd)

Explore other Zonisamide formulations Explore other Zonisamide 50mg capsules suppliers

Stability Notes

Store in an airtight container. Protect from light.

Provenance

This compatibility recommendation is derived from Zonegran 50mg capsules (Advanz Pharma).

Use with caution

Zopiclone 3.75mg tablets (A A H Pharmaceuticals Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Accord-UK Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Almus Pharmaceuticals Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Bristol Laboratories Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Flamingo Pharma (UK) Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Medihealth (Northern) Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Milpharm Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Novumgen Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Use with caution

Zopiclone 3.75mg tablets (Phoenix Healthcare Distribution Ltd)

Explore other Zopiclone formulations Explore other Zopiclone 3.75mg tablets suppliers

Stability Notes

Protect from light. Protect from moisture. Max 28 days in MCA.

Provenance

This compatibility recommendation is derived from Zimovane LS 3.75mg tablets (Sanofi) and Zopiclone 3.75mg tablets (Accord Healthcare Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.